Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aclaris Therapts
(NQ:
ACRS
)
3.630
-0.280 (-7.16%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Aclaris Therapts
< Previous
1
2
3
4
Next >
These 2 Biotech Stocks Made Big Monday Moves
March 06, 2023
Find out which was the winner and which was the loser.
Via
The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
March 06, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...
Via
Benzinga
As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris
March 06, 2023
Aclaris Therapeutics Inc (NASDAQ: ACRS) flunked a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 06, 2023
On Monday, 36 companies set new 52-week lows.
Via
Benzinga
Why Aclaris Therapeutics Is Crashing Today
March 06, 2023
The company announced disappointing results from a phase 2a clinical study.
Via
The Motley Fool
Why Aclaris Therapeutics Stock Is Plunging Today
March 06, 2023
Via
Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
February 27, 2023
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
March 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...
Via
Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
December 05, 2022
Via
Benzinga
Looking Into Aclaris Therapeutics Return On Capital Employed
August 09, 2022
Via
Benzinga
Recap: Aclaris Therapeutics Q1 Earnings
May 10, 2022
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
March 06, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
December 04, 2022
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built...
Via
Talk Markets
10 Best Stocks to Buy Now in December
December 01, 2022
These beaten-down stocks have significant upside.
Via
The Motley Fool
Aclaris Therapeutics: Q2 Earnings Insights
August 03, 2022
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via
Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
June 08, 2022
According to data from Benzinga Pro, during Q1, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.45 million. Despite a 17.61% increase in earnings, the company posted a loss of $18.79...
Via
Benzinga
Airbnb And 3 Other Stocks Insiders Are Selling
April 26, 2022
Although gold futures traded higher this morning on Tuesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
October 06, 2022
Upgrades
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop
January 12, 2022
Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52. The U.S...
Via
Benzinga
50 Biggest Movers From Yesterday
January 13, 2022
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 12, 2022
Gainers Immuron (NASDAQ:IMRN) shares rose 36.6% to $3.58 during Wednesday's regular session. Trading volume for this security as of 12:32 EST is 35.0 million, which is...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet
January 12, 2022
Midway through trading Wednesday, the Dow traded up 0.26% to 36,346.85 while the NASDAQ rose 0.77% to 15,270.07. The S&P also rose, gaining, 0.57% to 4,739.98. The U.S. has...
Via
Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
January 12, 2022
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing...
Via
Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
January 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...
Via
Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
November 02, 2021
Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q3 sales of $1.66 million. Earnings fell to a loss of $20.30 million, resulting in a 12.71% decrease from last...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.